AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021
Sep 11, 2021
31580_dirs_2021-09-10_4e83468b-aa6e-45c3-a9d3-f9c214cbaba9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-09-01
Reporting Person: Gheuens Sarah (Chief Medical Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 3462 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $38.72 | 2029-12-02 | Common stock (6044.0) | Direct | |
| Restricted stock units | $ | Common stock (1667.0) | Direct | ||
| Restricted stock units | $ | Common stock (6486.0) | Direct | ||
| Restricted stock units | $ | Common stock (9375.0) | Direct | ||
| Stock option (right to buy) | $56.68 | 2031-02-10 | Common stock (3243.0) | Direct |
Footnotes
F1: This option was granted on December 2, 2019. The shares underlying this option vest as to 25% of the underlying shares on December 2, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2: The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.
F5: The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022.
F6: This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.